Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
Site Search
Showing 11 - 14 of 14 results
News
|
Nov. 16, 2022
|
3 min read
Even though I haven't cultured for nontuberculous mycobacteria, I was excited to learn more about the treatment for the bacteria in people with cystic fibrosis during the virtual session at the North American Cystic Fibrosis Conference.
Meagan Helmick
|
3 min read
The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.
News
|
May 28, 2020
|
2 min read
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
News
|
March 25, 2013
|
1 min read